Latest Feature

Wound care by the numbers: Q&A with Alliqua CEO Dave Johnson

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

Podcast: Medtech legends and leaders on the state of medical device innovation

MassDevice.com brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.

CardioMEMS took 11 years to pay off, but for Boston Millennia it was worth it

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

Podcast: Haemonetics CEO Brian Concannon at MassDevice.com's DeviceTalks

Haemonetics CEO Brian Concannon discusses how the company will transform blood management in the coming years at MassDevice.com's DeviceTalks Boston event.

Calhoun Vision aims to disrupt ophthalmology with its light-adjustable lens

Calhoun Vision CEO Verne Sharma tells MassDevice.com why his company's light-adjustable lens will disrupt the practice of ophthalmology.

Subscribe to the MassDevice
Newsletter
Enter your email:

Need Medtech news in a minute? We Deliver!


MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

Mixed results for nerve stim in heart failure for Boston Scientific, Cyberonics

September 2, 2014 by Brad Perriello

Vagus nerve stimulation for heart failure flunks a Boston Scientific clinical trial but passes a Cyberonics study, but the question is clouded by the more rigorous, sham-arm structure of the Boston Scientific trial.

Mixed results for nerve stim in heart failure for Boston Scientific, Cyberonics

Secant Medical escapes pelvic mesh cases

September 2, 2014 by Brad Perriello

Secant Medical is dismissed from hundreds of personal injury lawsuits brought over pelvic mesh it made for Boston Scientific and Johnson & Johnson.

Secant Medical escapes pelvic mesh cases

Boston Scientific closes $415 Bayer interventions buy

September 2, 2014 by Brad Perriello

Boston Scientific says it's closed the $415 million acquisition of Bayer AG's interventions unit, nearly doubling the size of its peripherals business.

Boston Scientific closes $415 Bayer interventions buy

Boston Scientific (NYSE:BSX) said today that it closed on the $415 million cash buyout of Bayer AG's interventional unit it announced last May.

Renal denervation isn't dead, despite Medtronic trial's failure

September 2, 2014 by Brad Perriello

The failure of Medtronic's Symplicity 3 trial doesn't mean the end of renal denervation in treated resistant hypertension, especially in Europe, but future studies face a high bar set by the Medtronic trial's sham control arm.

Renal denervation isn't dead, despite Medtronic trial's failure

Ex-ArthroCare CEO Baker draws 20 years

September 2, 2014 by Brad Perriello

Ex-ArthroCare CEO Michael Baker draws a 20-year prison sentence and former CFO Michael Gluk is sentenced to 10 years after being found guilty of defrauding investors.

Ex-ArthroCare CEO Baker draws 20 years

Diabetes: Medtronic warns on insulin pump overdose | MassDevice.com On Call

September 2, 2014 by Arezu Sarvestani

Medtronic issues a warning letter to MiniMed Paradigm pump users after receiving reports that some patients had accidentally given themselves overdoses of insulin.

MASSDEVICE ON CALL — FDA medical device regulators reported this month that industry giant Medtronic (NYSE:MDT) issued a recall affecting nearly 560,000 units of its MiniMed Paradigm Infusion pumps.

Medtronic is not asking for the devices back, but is advising users to take extra care when programming their insulin dosage. The company has received reports that patients have accidentally programmed their insulin pumps to deliver the maximum bolus amount.

Sign up to get our free newsletters delivered straight to your inbox

The FDA report follows Medtronic's March 2014 letter to customers, in which the company cautioned users about accidental button pressing and advised that users always double-check their dosage on the pump's display.

ArthroCare executives found guilty of defrauding investors | Medtech legal news for the week of September 1, 2014

September 1, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: ArthroCare ex-CEO faces 30-year sentence for fraud; Shareholders sue Edap following FDA slip; Ex-sales rep wins class action status in lawsuit against Stryker; Another Covidien shareholder sues over Medtronic deal; Respiratory rivals ResMed, BMC each tally wins in Trade Commission ruling

ArthroCare ex-CEO faces 30-year sentence for fraud

August 25, 2014 by Arezu Sarvestani

ArthroCare ex-CEO faces 30-year sentence for fraud
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp